Holen Sie sich die Stockscreener-App
359.40
0.11%
0.40
Schlusskurs vom Vortag:
$359.00
Offen:
$358.76
24-Stunden-Volumen:
887.78K
Relative Volume:
1.11
Marktkapitalisierung:
$14.10B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$42.23M
KGV:
339.06
EPS:
1.06
Netto-Cashflow:
$150.33M
1W Leistung:
+1.11%
1M Leistung:
+13.39%
6M Leistung:
+54.18%
1J Leistung:
+31.78%
1-Tages-Spanne:
$358.36
$360.00
1-Wochen-Bereich:
$355.16
$362.41
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Vergleichen Sie PEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
359.40 | 14.08B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Halper Sadeh LLC Investigates Penumbra and RAPT Transactions - Intellectia AI
The $14.5 Billion Clot-Bust: Boston Scientific’s Bold Bet on Penumbra Signals a New Era of Medtech Giants - FinancialContent
Strs Ohio Cuts Stock Holdings in Penumbra, Inc. $PEN - MarketBeat
EFG Asset Management North America Corp. Acquires 3,631 Shares of Penumbra, Inc. $PEN - MarketBeat
Boston Scientific to acquire Alameda-based Penumbra for $14.5 billion - MSN
Penumbra launches next-gen Lightning Flash 3.0 thrombectomy system - MassDevice
Fed Meeting: Is Penumbra Inc likely to announce a buybackJuly 2025 Rallies & Daily Profit Focused Stock Screening - baoquankhu1.vn
Boston Scientific Penumbra Deal Recasts Growth Prospects In Thrombectomy And Neurovascular - Sahm
Baillie Gifford & Co. Sells 13,581 Shares of Penumbra, Inc. $PEN - MarketBeat
Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. - Barron's
Price Over Earnings Overview: Penumbra - Benzinga
Boston Scientific announces agreement to acquire Penumbra, Inc. - Quantisnow
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PEN, DBRG, FFIC, and FOLD - GlobeNewswire
Halper Sadeh Investigates Potential Securities Violations by Penumbra, Exact Sciences, DigitalBridge, and Flushing Financial - Intellectia AI
Halper Sadeh LLC Encourages PEN, EXAS, DBRG, FFIC Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Boston Sci secures CE mark for Embold system - BioWorld MedTech
Penumbra (NYSE:PEN) Sets New 52-Week HighWhat's Next? - MarketBeat
Penumbra Inc stock hits all-time high at 352.3 USD By Investing.com - Investing.com Nigeria
Halper Sadeh LLC Encourages PEN, FONR, GDOT Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Halper Sadeh Investigates Penumbra and Others for Potential Violations - Intellectia AI
Risk Report: Is ALTGs ROE strong enoughJuly 2025 Big Picture & Weekly Setup with High ROI Potential - baoquankhu1.vn
Boston Scientific to acquire Penumbra (NYSE: PEN) in $14.5B deal - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
3 takeaways from Boston Scientific’s $14.5B Penumbra deal - MedTech Dive
Boston Scientific to Acquire Alameda-Based Penumbra for $14.5 Billion - alamedapost.com
Penumbra Inc stock hits all-time high at 352.3 USD - Investing.com
Penumbra (PEN) Sees Downgrade with Revised Price Target from Can - GuruFocus
Penumbra shares soar pre-market — what is the Boston Scientific agreement? - MSN
Boston Scientific to Acquire Penumbra - Diagnostic and Interventional Cardiology
Penumbra, Inc. (PEN): Investor Outlook on Healthcare Innovator with Strong Revenue Growth - directorstalkinterviews.com
Boston Scientific to acquire Penumbra, expanding cardiovascular portfolio - Today's Medical Developments
Penumbra (PEN) climbs to all-time high on $14.5-billion merger - MSN
Penumbra Shares Soar Pre-MarketWhat Is The Boston Scientific Agreement? - Menafn
Aug Sectors: What analysts say about Penumbra Inc stock2025 Big Picture & Low Drawdown Trading Techniques - baoquankhu1.vn
UnitedHealth Stock Slips Amid Medicare Investigation; Boston Scientific to Acquire Penumbra for $14.5B - Intellectia AI
Boston Scientific to acquire Penumbra for enterprise value of ~$14.5B - MSN
Halper Sadeh Investigates Penumbra and Calavo Transactions for Shareholder Rights - Intellectia AI
(PEN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Penumbra (NYSE:PEN) Rating Lowered to Hold at Baird R W - MarketBeat
Penumbra (NYSE:PEN) Downgraded by Leerink Partnrs to Hold - MarketBeat
US-based Penumbra preliminary revenue up 22% Q4 2025 - Medical Buyer
Boston Scientific to acquire Penumbra for $14.5 billion By Investing.com - Investing.com Nigeria
RTW Biotech Opp.Boston Scientific to acquire Penumbra - Research Tree
Penumbra (NYSE:PEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
PEN Downgraded to Hold by Jefferies; Price Target Raised | PEN S - GuruFocus
Boston Scientific to Acquire Penumbra in Cash-Stock Merger - The Globe and Mail
Penumbra (PEN) Receives Neutral Rating with Raised Price Target by Citigroup | PEN Stock News - GuruFocus
PEN: Baird Downgrades Penumbra to 'Neutral', Raises Price Target - GuruFocus
PEN: Truist Securities Downgrades Penumbra to Hold | PEN Stock N - GuruFocus
Penumbra stock hits 52-week high at $321.47 By Investing.com - Investing.com Nigeria
Penumbra Inc. to be Sold to Boston Scientific for $374 per Share - Intellectia AI
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):